Human cardiac organoids to model COVID-19 cytokine storm induced cardiac injuries.
Dimitrios C ArhontoulisCharles M KerrDylan RichardsKelsey TjenNathaniel HyamsJefferey A JonesKristine Deleon-PennellDonald MenickHanna BräuningerDiana LindnerDirk WestermannYing MeiPublished in: Journal of tissue engineering and regenerative medicine (2022)
Acute cardiac injuries occur in 20%-25% of hospitalized COVID-19 patients. Herein, we demonstrate that human cardiac organoids (hCOs) are a viable platform to model the cardiac injuries caused by COVID-19 hyperinflammation. As IL-1β is an upstream cytokine and a core COVID-19 signature cytokine, it was used to stimulate hCOs to induce the release of a milieu of proinflammatory cytokines that mirror the profile of COVID-19 cytokine storm. The IL-1β treated hCOs recapitulated transcriptomic, structural, and functional signatures of COVID-19 hearts. The comparison of IL-1β treated hCOs with cardiac tissue from COVID-19 autopsies illustrated the critical roles of hyper-inflammation in COVID-19 cardiac insults and indicated the cardioprotective effects of endothelium. The IL-1β treated hCOs thus provide a defined and robust model to assess the efficacy and potential side effects of immunomodulatory drugs, as well as the reversibility of COVID-19 cardiac injuries at baseline and simulated exercise conditions.
Keyphrases
- coronavirus disease
- sars cov
- left ventricular
- respiratory syndrome coronavirus
- liver failure
- nitric oxide
- induced pluripotent stem cells
- physical activity
- intensive care unit
- drug induced
- genome wide
- high intensity
- single cell
- hepatitis b virus
- dna methylation
- risk assessment
- acute respiratory distress syndrome
- mechanical ventilation